Examkin

Soru

Zorluk: OrtaMonitoring and Treatment Evaluation

A 64-year-old woman comes to the primary care clinic for a routine follow-up. Six months ago, she was diagnosed with symptomatic paroxysmal atrial fibrillation and was subsequently started on oral amiodarone. She reports that her palpitations have completely resolved and she has been able to resume her daily 2-mile walks without shortness of breath, fatigue, or cough. Her other medical history is unremarkable. Current medications include amiodarone and apixaban. Vital signs are within normal limits. Physical examination shows a regular rate and rhythm with no murmurs, and clear lungs bilaterally. Which of the following diagnostic tests are indicated for the routine ongoing monitoring of this patient's antiarrhythmic therapy? (Select all that apply)

  1. Serum aminotransferasesCevap
  2. Serum thyroid-stimulating hormoneCevap
  3. C
    Serum creatinine
  4. D
    Prothrombin time and international normalized ratio
  5. E
    Complete blood count with differential

Cevap

Serum aminotransferases and Serum thyroid-stimulating hormone
Amiodarone is an iodine-rich class III antiarrhythmic agent associated with several long-term tissue toxicities, most notably involving the thyroid, liver, and lungs. Routine monitoring is essential to detect early asymptomatic dysfunction. Current guidelines strictly recommend checking serum aminotransferases (AST and ALT) and a serum thyroid-stimulating hormone (TSH) level at baseline and every 6 months during therapy. Hepatic toxicity is typically asymptomatic but can progress to cirrhosis if unmonitored. Thyroid dysfunction can manifest as either amiodarone-induced hypothyroidism (more common) or thyrotoxicosis.

Adım Adım Çözüm

1
Identify the primary medications the patient is taking and their associated indications.
The patient is taking amiodarone for paroxysmal atrial fibrillation and apixaban for stroke prophylaxis.
Establishes the pharmacologic targets for ongoing monitoring.
2
Recall the specific organ toxicities associated with chronic amiodarone therapy.
Amiodarone causes pulmonary, thyroid, hepatic, ophthalmic, and dermatologic toxicities.
Narrows down the potential laboratory and clinical monitoring requirements to the affected organ systems.
3
Determine the guideline-recommended timeline for amiodarone monitoring.
Guidelines recommend checking liver function tests (aminotransferases) and thyroid function (TSH) at baseline and every 6 months.
Selects the precise laboratory tests appropriate for a 6-month asymptomatic follow-up.
4
Evaluate the need for monitoring the patient's anticoagulant.
The patient is on apixaban. While amiodarone strongly interacts with warfarin (requiring INR monitoring), apixaban does not require routine coagulation monitoring.
Eliminates PT/INR from the required monitoring checklist.

Anahtar Kavram

Chronic amiodarone therapy requires routine monitoring of thyroid function (TSH) and hepatic function (aminotransferases) at baseline and every 6 months due to the risk of asymptomatic organ toxicity.
Bu soruyu puanla

Konular

Monitoring and Treatment Evaluation

Bu konudan daha fazla soru